Explore a little further

treatment

Stories and perspectives from Daytrade News.

From Daytrade News

5 stories shown · Newest added
Daytrade News

Apnimed Plans $160 Million IPO for Sleep Apnoea Treatment Development

Apnimed is preparing for a $160 million initial public offering on the Nasdaq to support the development of its lead therapy for obstructive sleep apnoea (OSA). The Massachusetts-based biotech aims to offer 10 million shares priced between $14 and $16 each, with the potential to…

More perspectives

Across our publications

A selection of related stories